Shareholders Foundation, Inc.

NASDAQ:PLSE Investor Alert: Lawsuit Alleges Misleading Statements by Pulse Biosciences, Inc.

A lawsuit was filed on behalf of investors in Pulse Biosciences, Inc. (NASDAQ:PLSE) shares over alleged securities laws violations.


San Diego, CA -- (SBWIRE) -- 03/02/2022 -- An investor, who purchased NASDAQ: PLSE shares, filed a lawsuit in the over alleged Securities Laws violations by Pulse Biosciences, Inc.

Investors who purchased shares of Pulse Biosciences, Inc. (NASDAQ: PLSE) have certain options and for certain investors are short and strict deadlines running. Deadline: April 18, 2022. NASDAQ: PLSE investors should contact the Shareholders Foundation at or call +1(858) 779 - 1554.

In October 2020, Pulse initiated its investigational device exemption ("IDE") study to evaluate the treatment of sebaceous hyperplasia lesions using the CellFX System.

On February 8, 2022, Pulse Biosciences, Inc announced that the U.S. Food and Drug Administration ("FDA") concluded there was insufficient clinical evidence to support the Company's 510(k) submission to expand the label for the CellFX System to treat sebaceous hyperplasia. Among other things, the FDA found "that the Company had not met the primary endpoints of the sebaceous hyperplasia FDA-approved IDE study."

Shares of Pulse Biosciences, Inc. (NASDAQ: PLSE) declined from $13.36 per share on January 26, 2022 to as low as $6.34 per share on February 9, 2022.

The plaintiff claims that between January 12, 2021 and February 7, 2022, the Defendants failed to disclose to investors that the IDE study evaluating the use of the CellFX System to treat sebaceous hyperplasia lesions failed to meet its primary endpoints, that, as a result, there was a substantial risk that the FDA would reject Pulse's 510(k) submission seeking to expand the label for the CellFX System to treat sebaceous hyperplasia lesions, and that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Those who purchased shares of Pulse Biosciences, Inc. (NASDAQ: PLSE) have certain options and should contact the Shareholders Foundation.

Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.